Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Novocure Ltd (NVCR)  
$12.64 0.40 (3.31%) as of 4:30 Fri 4/26


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 101,800,000
Market Cap: 1.29(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $11.13 - $82.51
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   NovoCure is an oncology company with a platform technology called Tumor Treating Fields. Co. is focusing on commercial adoption of Optune and NovoTTF-100L. Optune is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in combination with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Co. also has approval to market Optune for the treatment of GBM in the European Union, Japan and certain other countries. NovoTTF-100L is approved by the FDA to treat malignant pleural mesothelioma in combination with chemotherapies.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 10,224 10,606 13,200 438,231
Total Sell Value $164,332 $169,164 $235,406 $41,505,546
Total People Sold 2 3 4 10
Total Sell Transactions 6 7 11 54
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 906
  Page 1 of 37  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Leonard Frank X EVP, Pres., Novocure Oncology   •       –      –    2024-03-04 4 S $16.01 $13,448 D/D (840) 160,098 26%     
   Groenhuysen Wilhelmus Cm Chief Operating Officer   •       –      –    2024-03-04 4 S $16.01 $19,484 D/D (1,217) 251,235 26%     
   Leonard Frank X EVP, Pres., Novocure Oncology   •       –      –    2024-03-01 4 S $16.03 $26,909 D/D (1,679) 160,938 25%     
   Groenhuysen Wilhelmus Cm Chief Operating Officer   •       –      –    2024-03-01 4 S $16.03 $33,769 D/D (2,107) 252,452 25%     
   Groenhuysen Wilhelmus Cm Chief Operating Officer   •       –      –    2024-02-28 4 S $16.14 $37,177 D/D (2,303) 254,559 24%     
   Leonard Frank X EVP, Pres., Novocure Oncology   •       –      –    2024-02-28 4 S $16.14 $33,545 D/D (2,078) 162,617 24%     
   Leupin Nicolas Chief Medical Officer   •       –      –    2024-02-27 4 A $16.30 $833,321 D/D 51,124 51,124     -
   Ben Arye Barak General Counsel   •       –      –    2024-02-27 4 A $16.30 $1,333,324 D/D 81,799 117,122     -
   Cordova Ashley Chief Financial Officer   •       –      –    2024-02-27 4 A $16.30 $1,666,659 D/D 102,249 219,867     -
   Weinberg Uri Chief Innovation Officer   •       –      –    2024-02-27 4 A $16.30 $1,333,324 D/D 81,799 171,148     -
   Puri Michal Nath Chief Human Resources Officer   •       –      –    2024-02-27 4 A $16.30 $1,166,656 D/D 71,574 109,167     -
   Groenhuysen Wilhelmus Cm Chief Operating Officer   •       –      –    2024-02-27 4 A $16.30 $766,654 D/D 47,034 256,862     -
   Leonard Frank X EVP, Pres., Novocure Oncology   •       –      –    2024-02-27 4 A $16.30 $1,666,659 D/D 102,249 164,695     -
   Giladi Moshe Chief Science Officer   •       –      –    2024-02-27 4 A $16.30 $833,321 D/D 51,124 69,771     -
   Leonard Frank X EVP, Pres., Novocure Oncology   •       –      –    2024-01-04 3 IO $0.00 $0 D/D 0 17,178 -9%     
   Leonard Frank X EVP, Pres., Novocure Oncology   •       –      –    2024-01-04 3 IO $0.00 $0 D/D 0 45,268 -9%     
   Ben Arye Barak General Counsel   •       –      –    2023-12-31 4 A $12.69 $1,624 D/D 128 35,323     -
   Groenhuysen Wilhelmus Cm Chief Operating Officer   •       –      –    2023-12-31 4 A $12.69 $38 D/D 3 209,828     -
   Shah Pritesh Chief Growth Officer   •       –      –    2023-11-07 4 AS $12.65 $4,832 D/D (382) 124,511 5%     
   Cordova Ashley Chief Financial Officer   •       –      –    2023-11-02 4 OE $11.46 $2,006 D/D 175 117,618     -
   Cordova Ashley Chief Financial Officer   •       –      –    2023-10-31 4 OE $7.15 $170,447 D/D 17,793 117,443     -
   Cordova Ashley Chief Financial Officer   •       –      –    2023-09-01 4 S $21.82 $19,265 D/D (883) 99,650 39%     
   Shah Pritesh Chief Growth Officer   •       –      –    2023-09-01 4 S $21.82 $5,956 D/D (273) 124,893 39%     
   Groenhuysen Wilhelmus Cm Chief Operating Officer   •       –      –    2023-09-01 4 S $21.82 $6,414 D/D (294) 209,825 39%     
   Cordova Ashley Chief Financial Officer   •       –      –    2023-08-02 4 S $30.25 $34,607 D/D (1,144) 100,533 58%     
  906 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 37
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us